Economic Impact of Medicare Part D on US Community Pharmacy Operations: A National Survey

The introduction of generic medicines in 1984 marked a significant shift in pharmaceutical economics. However, prescription decisions are still largely made by doctors, especially in long-term care facilities, where older residents rarely have a say in their treatment. As the need for long-term care grows and patient involvement remains limited, it is crucial to examine how policies like Medicare Part D affect prescribing practices in these settings. Earlier studies show mixed results on the program's impact on drug costs and generic use, yet little research focuses on how it has changed doctors' prescribing behaviour in long-term care centres. ^[1],[2]  Initially, on December 8, 2003, the first implementation of the Medicare Modernization Act (MMA) provided a voluntary outpatient prescription drug benefit. However, it was not officially available for outpatient use and remained restricted to past memoranda. Therefore, to observe the impact on patients starting on January 1, 2006, it was crucial for healthcare professionals and patients alike. The main barrier to demonstrating the benefits of this law for long-term care is particularly significant for seniors dealing with chronic conditions. ^[1],[2] The cost of national prescription drugs continues to rise, surpassing $328 billion in 2016. That year, patients covered about 13.7% of total prescription spending directly out of pocket for their medication. ^[3] Long-term care pharmacies face hidden costs. A new financial analysis has raised concerns about senior care in America, revealing that efforts to lower drug prices may unintentionally endanger the pharmacies serving vulnerable elderly patients. A report from the Senior Care Pharmacy Coalition (SCPC), analyzed by ATI Advisory, suggests that the Long-Term Care (LTC) pharmacy sector is facing a financial crisis. The data shows that the combined effects of Medicare Part D price negotiations for 2026 and 2027 could force the average LTC pharmacy to operate at nearly a 3% loss in two years. The Unintended Consequences of Price Negotiation: Although the push for lower drug prices generally benefits consumers, the structure of Medicare Part D poses a unique challenge for LTC pharmacies. Unlike retail drugstores, these pharmacies offer specialized, high-touch clinical services to patients in nursing homes and assisted living facilities—patients often dealing with multiple chronic conditions and physical impairments. Since 75% of LTC pharmacy revenue comes from Medicare Part D, these businesses traditionally relied on reimbursements from brand-name drugs to cover their specialized care. As those prices are negotiated down without changes to the reimbursement model, this approach becomes unsustainable. ^[6]  The report serves as a stark warning: without intervention, the “maximum possible” prices for 2027 could dismantle the sector. Actual negotiated pharmacy prices may end up even lower than the legal maximums analyzed, leading to a bleaker economic reality. A Looming Crisis for Seniors: The human cost of this economic struggle is projected to be severe. An earlier survey of SCPC members painted a disturbing picture of what 2026 might bring if changes do not occur: 60% of respondents expect to close their pharmacies entirely. 90% expect to lay off staff. 80% plan to cut back on services for seniors. ^{[4],[5],[7],[8],[9]}  The impact will feel strongest in rural America, where options are already limited. If specialized pharmacies shut down, millions of seniors could lose access to the necessary medication management they need to survive. 

The Proposed Solution: H.R. 5031* 

Alan Rosenbloom, President and CEO of the SCPC, emphasized that while the industry supports lower patient costs, the current path is unsustainable. "This new report confirms what we already know," Rosenbloom said, noting serious consequences expected to begin in 2026 and worsen by 2027. However, a legislative option exists. The SCPC is backing H.R. 5031, also known as the Preserving Patient Access to Long-term Care Pharmacies Act. Introduced by Representatives Beth Van Duyne (R-TX) and Brad Schneider (D-IL), this bipartisan bill seeks to repair the broken economic model. The legislation suggests a $30 supplemental supply fee for each specific prescription. This fee is intended to cover the actual costs of dispensing and the specialized clinical services LTC pharmacies offer, separating their survival from fluctuating brand-name drug prices. As the government prepares to negotiate prices for 15 additional drugs in 2027, time is running out. Without the relief proposed in H.R. 5031, the pharmacies caring for America’s oldest citizens may not withstand the changes meant to assist them. ^{[[10],[11],[12],[13]]*} The main focus of reviewing the topic of financial responses to Medicare Part D should center on the financial health of independent pharmacies for two simple reasons. Many patients on Medicaid managed care and Medicare Part D live in rural and inner-city areas, where independent pharmacies are often the only nearby option. If these pharmacies close, patients may struggle to get their medications. Additionally, with fewer pharmacies in an area, managed care organizations have less leverage to negotiate better payment rates. ^[14],[15] Overall, the review content is useful for analyzing the management of critical conditions in cases of chronic diseases.

OBJECTIVES:

• To compare pre- and post-Medicare Part D data to assess the impact on cost and budget management within Long-Term Care (LTC) pharmacy operations.
• To analyze the influence of negotiation strategies on the annual revenue of LTC providers."
• To identify effective schemes and policies that could mitigate the total cost of medication for LTC patients.
• To analyze the challenges Medicare providers face in structuring their benefit schemes (Hospital Insurance, Medical Insurance, Private Plans, Prescription Drugs) to balance beneficiary cost coverage with provider sustainability. 
• To assess the impact of beneficiary cost-sharing (premiums, deductibles, co-insurance) on the financial landscape of Medicare Part D providers.

METHODOLOGY:

Study Design:

Both studies used observational research methods but had different structures. The first study took a retrospective longitudinal approach. It analysed prescription records before and after Medicare Part D was implemented. It used a quasi-experimental framework with a difference-in-difference (DID) approach to measure the policy's impact over time. The second study used a nationwide cross-sectional survey design. This survey was conducted at a single point in time to assess pharmacists' views on the financial effects of Medicare Part D. So, while Study 1 concentrated on changes in prescription behaviour using past data, Study 2 looked at financial perceptions based on self-reported survey answers.

Data Source and Setting:

The first study used electronic prescription records from several long-term care facilities in Pennsylvania, collected between 2004 and 2007. The dataset included patient demographics, physician identifiers, diagnosis information, and drug coverage status. The second study collected data through an online structured questionnaire sent to licensed pharmacists working in independent and chain community pharmacies across the United States in 2013. Email invitations were sent through a third-party vendor to ensure geographic representation. Therefore, Study 1 relied on administrative pharmacy data from institutional settings, while Study 2 used survey responses from community pharmacy professionals.

Study Population:

In the first study, the focus was on individual prescription orders for residents of long-term care facilities. Participants were divided into treatment and control groups based on their Medicare Part D enrollment status. This included dual enrollees, voluntary enrollers, eligible non-duals, and non-enrolled individuals. In contrast, the second study looked at practicing pharmacists, including staff pharmacists, managers, and pharmacy owners or part-owners from rural, suburban, and urban areas. Therefore, Study 1 explored patient-level prescription behaviour, while Study 2 examined pharmacist-level financial experiences.

Inclusion Criteria:

Licensed pharmacists practicing in the United States.

Pharmacists work in:

5. Independent community pharmacies (1 to 3 locations) 
5. Chain pharmacies (4 or more locations)

Pharmacies that accept Medicare Part D plans.

Pharmacists practice in rural, suburban, or urban settings.

Participants who completed the online survey voluntarily.

Exclusion Criteria:

• Non-pharmacist respondents, such as pharmacy technicians and non-pharmacist owners.
• Pharmacists whose main practice site did not accept Medicare Part D.
• Incomplete or invalid survey responses.
• Duplicate submissions (if any).

Data Collection Procedure:

• Email addresses of practicing pharmacists were obtained from a third-party vendor to ensure random and geographic representation.
• A total sample of pharmacists working in independent and chain community pharmacies was chosen.
• An online questionnaire with 43 items was sent out via email using an internet-based survey platform.
• Multiple email reminders were sent about once a month to boost response rates.
• Participation was voluntary and anonymous.
• The questionnaire gathered information on demographics, prescription volume, financial performance, MTM services, and views on Medicare Part D.
• Responses from non-pharmacists and pharmacists who do not accept Medicare Part D were excluded. Completed surveys were checked for validity and completeness before any statistical analysis.
• The finalized dataset was analysed using descriptive statistics and regression models.

Comparison of Studies:

The study suggests that Medicare Part D has shifted the market toward a chain-dominated duopoly. Independent pharmacies, especially in rural areas, are important for healthcare access. However, they face a high risk of closure because reimbursement rates do not keep pace with the increased prescription volume required by the program.

Sample Size:

Survey emails went out to 7,828 pharmacists. Of those, 1,885 emails reached recipients successfully. 419 pharmacists responded, which resulted in an adjusted response rate of 22.3%. After excluding some responses, the final analysis included 406 pharmacists.

Statistical Analysis:

The study used a Difference-in-Difference (DID) analytical framework to estimate the impact of Medicare Part D. Statistical models included:

• Descriptive statistics (frequencies and percentages)
• Chi-square tests for subgroup comparisons
• Logistic regression modelling to identify predictors of financial performance
• Pie-chart format.
• Research related question answer formularies.
• Percentage of respondents.
• Metric VS Ownership Insights.

Analysis Parameters

5. Base Case: 2027 Negotiated Price at the "Maximum Allowed by Law."
5. Baseline Outcome: Average net loss of -2.8%.
5. Variable Tested: Negotiation Outcome Variance (± 10% from Maximum Allowed).
5. Threshold for Failure: -5.0% Net Margin (this is the "Rapid Insolvency" point where credit facilities usually freeze).

Sensitivity Table: Margine Elasticity*

RESULT:

While 75.6% of pharmacists reported steady or increased prescription volumes since Part D began in 2006, only 40.4% rated their pharmacy’s financial performance as “excellent” or “good.”

5. Location Disparity: Rural independent pharmacies faced the toughest challenges. 75.0% of owners said their financial performance was below average or poor.
5. Scale Advantage: Pharmacists in chain or high-volume settings, those dispensing over 300 prescriptions per day, were about three times more likely to report good financial performance than those in low-volume sites.
5. Operational Strain: Part D workflow disruptions, such as “point of dispensing” prescription switches and low reimbursement rates, made performance harder.
5. Pharmacy Ownership and Sustainability

The financial pressures from Part D have made it difficult for independent owners.

Under the Inflation Reduction Act (IRA), the implementation of drug price negotiations will threaten the long-term financial viability of the LTC pharmacy sector. Lower drug costs are beneficial to public health. The current reimbursement model does not separate "ingredient cost" from "clinical service cost." Without H.R. 5031, the average LTC pharmacy will incur a 3% operating loss by 2027, threatening care for 2 million vulnerable seniors.

The Economic “Value Gap”

LTC pharmacies get 75% of their revenue from Medicare Part D. Current analytics from ATI Advisory show the following:

5. Revenue Compression: Negotiated "Maximum Fair Prices" (MFP), cutting brand-name drug margins by up to 57%.
5. Service Subsidy Collapse: Historically, these margins funded 24/7 clinical support, specialized adherence packaging, and consultant pharmacist reviews, services that are not typically covered by standard dispensing fees.
5. Operational Risk: Survey data indicate that 60% of LTC pharmacies might close, and 90% expect staff layoffs if no relief is given.